Lam K, et al. American Association for Cancer Research® (AACR) Annual Meeting, April 2024
This poster describes data on a panel of CD28 costimulatory antibodies. T-cell engagers (TCEs) that engage the CD28 costimulatory receptor can enhance T-cell activation, proliferation, and anti-tumor activities, particularly in solid tumors. The panel of IgG and heavy chain-only CD28-binding antibodies do not display superagonist activity — a property that has been associated with toxicities. Integrating costimulatory molecules with TCE modalities may enable development of molecules with enhanced potency for difficult-to-treat cancers.
DOI: 10.1158/1538-7445.AM2024-1859
